Provided by Tiger Fintech (Singapore) Pte. Ltd.

ADiTx Therapeutics

9.66
+2.1628.83%
Volume:47.13M
Turnover:481.45M
Market Cap:3.05M
PE:0.00
High:12.30
Open:9.63
Low:8.06
Close:7.50
Loading ...

BRIEF-Aditxt Provides Update On Equity Line Of Credit, ATM Usage, And Outstanding Number Of Shares

Reuters
·
08 Nov 2024

Aditxt Inc: Shelf Utilization Inclusive of Eloc and Atm, Will Be Suspended During Stale Period From Monday, Nov 11

THOMSON REUTERS
·
08 Nov 2024

Aditxt Provides Update on Equity Line of Credit, Atm Usage, and Outstanding Number of Shares

THOMSON REUTERS
·
08 Nov 2024

BRIEF-Aditxt’s Target Acquisition Appili Therapeutics Announces Results Of Special Meeting Of Shareholders

Reuters
·
07 Nov 2024

Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

THOMSON REUTERS
·
07 Nov 2024

Appili Therapeutics Announces Results of Special Meeting of Shareholders

GlobeNewswire
·
07 Nov 2024

Aditxt announces Evofem secures voting agreements with investors for merger

TIPRANKS
·
06 Nov 2024

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger With Aditxt's Subsidiary Adifem

THOMSON REUTERS
·
06 Nov 2024

BRIEF-Evofem Secures Investor Support For Proposed Merger Through Voting Agreements

Reuters
·
06 Nov 2024

Evofem Secures Investor Support for Proposed Merger Through Voting Agreements

THOMSON REUTERS
·
06 Nov 2024

Aditxt announces ‘positive’ FDA feedback for Appili Therapeutics ATI-1801

TIPRANKS
·
31 Oct 2024

BRIEF-Aditxt’S Target Acquisition Appili Therapeutics Announces Alignment With FDA On Development Requirements For ATI-1801 Topical Antiparasitic Product NDA Submission

Reuters
·
31 Oct 2024

Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment With FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product Nda Submission

THOMSON REUTERS
·
31 Oct 2024

BRIEF-Appili Therapeutics Announces Alignment With FDA On Development Requirements For Ati-1801 Topical Antiparasitic Product NDA Submission

Reuters
·
31 Oct 2024

Appili Therapeutics Announces Alignment With FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product Nda Submission

THOMSON REUTERS
·
31 Oct 2024

Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

GlobeNewswire
·
31 Oct 2024